Companies including Daewon and Ahngook challeges to ezetimibe complex market

Korean companies are developing fierce competition in the market of complexes having the more powerful function to inhibit cholesterol than the combination of statin and ezetimibe.

They all are planning to launch their own generics in different times, but have the same goal to localize the market which has been monopolized by MSD.

According to the industry concerned on the 17^th, starting wi...